ABC Sees Double Opportunity For Wholesalers In Biosimilars
AmerisourceBergen is anticipating that the establishment of an FDA approval pathway for biosimilars under health care reform will have a real upside for drug wholesalers
You may also be interested in...
The onset of Lovenox generics could be a near-term reality in the U.S., though timing remains uncertain.
Voluntary hold on Propofol, Liposyn will negatively impact 2010 sales, though acquisition of Orchid will help make up the difference.
Sanofi-Aventis reduces Eloxatin competition: Sanofi-Aventis settled Eloxatin (oxaliplatin) patent infringement suits against Teva, Sandoz and Fresenius Kabi. Under the terms of the settlement the companies will stop selling their generic versions of the colon cancer drug on June 30 and resume marketing under a license on Aug. 9, 2012. The other terms of the settlement are confidential. Eloxatin's compound patent has expired but other patents cover the drug through 2016. As a result of generic competition, Sanofi's U.S. sales of Eloxatin fell from $1.4 billion in 2008 to $930 million in 2009. Hospira, Sun and Sun's U.S. subsidiary Caraco also market generic versions of Eloxatin. Sanofi has pending suits against MN Pharmaceuticals, Mayne Pharma and Actavis